Literature DB >> 12113472

Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration.

Guido W M Swart1.   

Abstract

Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a member of the immunoglobulin superfamily and belongs to a recent subgroup with five extracellular immunoglobulin-like domains (VVC2C2C2). ALCAM mediates both heterophilic (ALCAM-CD6) and homophilic (ALCAM-ALCAM) cell-cell interactions. While expressed in a wide variety of tissues, ALCAM is usually restricted to subsets of cells involved in dynamic growth and/or migration, including neural development, branching organ development, hematopoiesis, immune response and tumor progression. Recent structure-function analyses of ALCAM hint at how its cytoskeletal anchoring and the integrity of the extracellular immunoglobulin-like domains may regulate complex cellular properties in regard to cell adhesion, growth and migration. Accumulating evidence suggests that ALCAM expression may reflect the onset of a cellular program for homeostatic control of growth saturation, which induces either growth arrest or cell migration when the upper limits are exceeded.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12113472     DOI: 10.1078/0171-9335-00256

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  83 in total

1.  Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.

Authors:  Linlin Xu; Khalid S Mohammad; Hao Wu; Colin Crean; Bradley Poteat; Yinghua Cheng; Angelo A Cardoso; Christophe Machal; Helmut Hanenberg; Rafat Abonour; Melissa A Kacena; John Chirgwin; Attaya Suvannasankha; Edward F Srour
Journal:  Cancer Res       Date:  2016-09-07       Impact factor: 12.701

2.  Activated leukocyte cell adhesion molecule impacts on clinical wound healing and inhibits HaCaT migration.

Authors:  Andrew J Sanders; David G Jiang; Wen G Jiang; Keith G Harding; Girish K Patel
Journal:  Int Wound J       Date:  2011-08-04       Impact factor: 3.315

3.  CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis.

Authors:  Syed M A Abidi; Mohammad K Saifullah; Marie D Zafiropulos; Cara Kaput; Michael A Bowen; Calvin Cotton; Nora G Singer
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].

Authors:  E Kilic; K Milde-Langosch; V Müller; R Wirtz; M Ihnen
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

5.  Hierarchical organization of osteoblasts reveals the significant role of CD166 in hematopoietic stem cell maintenance and function.

Authors:  Brahmananda R Chitteti; Ying-Hua Cheng; Melissa A Kacena; Edward F Srour
Journal:  Bone       Date:  2013-01-28       Impact factor: 4.398

6.  Elevated ALCAM shedding in colorectal cancer correlates with poor patient outcome.

Authors:  Amanda G Hansen; Tanner J Freeman; Shanna A Arnold; Alina Starchenko; Celestial R Jones-Paris; Michael A Gilger; Mary K Washington; Kang-Hsien Fan; Yu Shyr; Robert D Beauchamp; Andries Zijlstra
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

7.  Generation of novel monoclonal antibodies for the enrichment and characterization of human corneal endothelial cells (hCENC) necessary for the treatment of corneal endothelial blindness.

Authors:  Vanessa Ding; Angela Chin; Gary Peh; Jodhbir S Mehta; Andre Choo
Journal:  MAbs       Date:  2014       Impact factor: 5.857

8.  Microarray studies on effects of Pneumocystis carinii infection on global gene expression in alveolar macrophages.

Authors:  Bi-Hua Cheng; Yunlong Liu; Xiaoling Xuei; Chung-Ping Liao; Debao Lu; Mark E Lasbury; Pamela J Durant; Chao-Hung Lee
Journal:  BMC Microbiol       Date:  2010-04-08       Impact factor: 3.605

9.  A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Authors:  Merete Thune Wiiger; Hege B Gehrken; Øystein Fodstad; Gunhild M Maelandsmo; Yvonne Andersson
Journal:  Cancer Immunol Immunother       Date:  2010-07-16       Impact factor: 6.968

10.  Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse.

Authors:  C Kahlert; H Weber; C Mogler; F Bergmann; P Schirmacher; H G Kenngott; U Matterne; N Mollberg; N N Rahbari; U Hinz; M Koch; M Aigner; J Weitz
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.